➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,456,360

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,456,360 protect, and when does it expire?

Patent 10,456,360 protects ONIVYDE and is included in one NDA.

This patent has fifteen patent family members in fourteen countries.

Summary for Patent: 10,456,360
Title:Stabilizing camptothecin pharmaceutical compositions
Abstract: Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.
Inventor(s): Drummond; Daryl C. (Lincoln, MA), Kirpotin; Dmitri B. (Revere, MA), Hayes; Mark Eamon (Mill Valley, CA), Noble; Charles (San Francisco, CA), Kesper; Kevin (Watertown, MA), Awad; Antoine M. (West Roxbury, MA), Moore; Douglas J. (Newton, MA), O'Brien; Andrew J. (Franklin, MA)
Assignee: Ipsen Biopharm Ltd. (GB)
Application Number:15/768,352
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Process; Dosage form;

Drugs Protected by US Patent 10,456,360

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ipsen Inc ONIVYDE irinotecan hydrochloride INJECTABLE, LIPOSOMAL;INTRAVENOUS 207793-001 Oct 22, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,456,360

PCT Information
PCT FiledOctober 15, 2016PCT Application Number:PCT/US2016/057247
PCT Publication Date:April 20, 2017PCT Publication Number: WO2017/066726

International Family Members for US Patent 10,456,360

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2016340153   Start Trial
Brazil 112018006922   Start Trial
Canada 3001467   Start Trial
China 108366965   Start Trial
European Patent Office 3362049   Start Trial
Hong Kong 1258407   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.